Slide 1: Fourth Quarter and Year End 2020 Results
K Pharm Fourth Quarter and Year End 2020 Results
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Forward-looking st
Slide 3: Q4/YE 2020 Results Call Participants
Q4/YE 2020 Results Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer
Slide 4: KemPharm: Q4/YE 2020 and Recent Highlights
KemPharm: Q4/YE 2020 and Recent Highlights AZSTARYS™ (KP415) Improved Financial Position - FDAhas approved AZSTARYS NDA - Multi-phase financial restructure process - Eligible to receive up to $468 million for completed regulatory and sales milestone payments - KMPH stock re-listed on Nasdaq effectiv
Slide 5: AZSTARYS Approval
AZSTARYS™ Approval v Announced FDA Approval of AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, Cll) ANew Once-Daily Treatment for ADHD Consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d- methylphenidate (d-MPH), co-formulated with immediate-release d-MPH
Slide 6: Partnership with Gurnet Point Capital and Corium, Inc.
Partnership with Gurnet Point Capital and Corium, Inc. + Worldwide license with an affiliate of Gurnet Point Capital (GPC) announced Sept 2019 o Corium, a GPC portfolio company, is leading all commercialization activities « License agreement includes a total of up to $483 million in upfront and mile
Slide 7: ADHD and ER Methylphenidate Market — 2019
ADHD and ER Methylphenidate Market — 2019 * ~$17.5 billion ADHD market with prescription growth of >4% year-over-year * The branded portion of the ADHD market was ~$7.4B in 2019 and more than 95% of these branded prescriptions are for extended release + Methylphenidate (MPH) accounted for approximat
Slide 8: Financial Update
Financial Update
Slide 9: Multi-Phase Financial Restructuring Completed
Multi-Phase Financial Restructuring Completed * Series of transactions enabled the restructure of the balance sheet and strengthened our financial position * Transactions culminated in aggregate gross proceeds of approximately $94 million, enabling KemPharm to: o Regain its listing on The Nasdaq Cap
Slide 10: Q4 2020 Financial Results
Q4 2020 Financial Results + Revenue and Net Loss o Revenue of $2.4M, primarily comprised of services revenue under the Corium consulting arrangement, compared to Q3 2020 service revenue of $1.9M o Net loss of ($4.9M), or ($1.07) per basic and diluted share, compared to net loss of ($6.0M), or ($2.90
Slide 11: FY 2020 Financial Results
FY 2020 Financial Results + Revenue and Net Loss o Revenue of $13.3M, primarily comprised of services revenue under the Corium and other consulting arrangements as well as regulatory milestone revenue of $5.0M, compared to FY 2019 revenue of $12.8M o Net loss of ($12.8M), or ($3.21) per basic and di
Slide 12: Q4 2020 Balance Sheet Update
Q4 2020 Balance Sheet Update - As of Dec 31, 2020, total cash’ was $4.3M, a decrease of $1.1M compared to Sep 30, 2020; forecasted cash burn rate of ~$1M/quarter o Based on existing resources, after taking into account balance sheet restructuring in Jan / Feb 2021 cash runway expected to fund operat
Slide 13: KemPharm: Q4/YE 2020 and Recent Highlights
KemPharm: Q4/YE 2020 and Recent Highlights AZSTARYS™ (KP415) Improved Financial Position - FDAhas approved AZSTARYS NDA - Multi-phase financial restructure process - Eligible to receive up to $468 million for completed regulatory and sales milestone payments - KMPH stock re-listed on Nasdaq effectiv
Slide 14: Pharm
K Pharm Fourth Quarter and Year End 2020 Results